This paper analyzes the negotiation process, which leads to basic research funding and price setting for new drugs in regulated health insurance markets. Its results bring answers to the following questions; should basic research be privately funded, publicly funded or produced by an independent lab? Under which conditions is public integration of basic research efficient? How do pharmaceutical prices respond to different organizations of basic research? We show that efficiency and prices are higher when basic research is integrated in the firm that commercializes the drug as compared to independent basic research. In both organizations, the higher the negotiation power of the research labs relative to the one of the public health authority is, the higher the prices and the efficiency are. We thereby confirm the traditional trade-off between price containment and dynamic efficiency. We identify one important exception to this trade-off. Indeed, public integration of basic research can result in lowest prices and highest efficiency, as compared to the other possible organizations, in particular when basic and applied research are highly complementary.

Research funding and price negotiation for new drugs / Francesca Barigozzi; Izabela Jelovac. - In: HEALTH ECONOMICS. - ISSN 1057-9230. - STAMPA. - 29:S1(2020), pp. -.83--.96. [10.1002/hec.4113]

Research funding and price negotiation for new drugs

Francesca Barigozzi
;
2020

Abstract

This paper analyzes the negotiation process, which leads to basic research funding and price setting for new drugs in regulated health insurance markets. Its results bring answers to the following questions; should basic research be privately funded, publicly funded or produced by an independent lab? Under which conditions is public integration of basic research efficient? How do pharmaceutical prices respond to different organizations of basic research? We show that efficiency and prices are higher when basic research is integrated in the firm that commercializes the drug as compared to independent basic research. In both organizations, the higher the negotiation power of the research labs relative to the one of the public health authority is, the higher the prices and the efficiency are. We thereby confirm the traditional trade-off between price containment and dynamic efficiency. We identify one important exception to this trade-off. Indeed, public integration of basic research can result in lowest prices and highest efficiency, as compared to the other possible organizations, in particular when basic and applied research are highly complementary.
2020
Research funding and price negotiation for new drugs / Francesca Barigozzi; Izabela Jelovac. - In: HEALTH ECONOMICS. - ISSN 1057-9230. - STAMPA. - 29:S1(2020), pp. -.83--.96. [10.1002/hec.4113]
Francesca Barigozzi; Izabela Jelovac
File in questo prodotto:
File Dimensione Formato  
Barigozzi Jelovac post print copertina.pdf

Open Access dal 15/06/2021

Tipo: Postprint
Licenza: Licenza per accesso libero gratuito
Dimensione 579.19 kB
Formato Adobe PDF
579.19 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/783798
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 5
social impact